Lucia Sergi Sergi

Lucia Sergi Sergi

Auto-generated profile, based on publicly available information

Lucia Sergi Sergi

San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Cancer Cell
Verified
Journal Article
Closed access
MPMichele De Palma
Michele De Palma
MARY ANNA VENNERIMARY ANNA VENNERI
MARY ANNA VENNERI
RGRossella Galli
Rossella Galli
LSLucia Sergi Sergi
Lucia Sergi Sergi
LPLetterio S. Politi
Letterio S. Politi
LNLuigi Naldini
Luigi Naldini

28 May 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EMEugenio Montini
Eugenio Montini
DCDaniela Cesana
Daniela Cesana
MSManfred Schmidt
Manfred Schmidt
FSFrancesca Sanvito
Francesca Sanvito
MPMaurilio Ponzoni
Maurilio Ponzoni
LNLuigi Naldini
Luigi Naldini

1 April 2009 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
EMEugenio Montini
Eugenio Montini
DCDaniela Cesana
Daniela Cesana
MSManfred Schmidt
Manfred Schmidt
FSFrancesca Sanvito
Francesca Sanvito
CBCynthia C. Bartholomae
Cynthia C. Bartholomae
LNLuigi Naldini
Luigi Naldini
γ-Retroviral vectors (γRVs), which are commonly used in gene therapy, can trigger oncogenesis by insertional mutagenesis. Here, we have dissected the contribution of vector design and viral integration site selection (ISS) to oncogenesis using an in vivo genotoxicity assay based on transplantation of vector-transduced tumor-prone mouse hematopoietic stem/progenitor cells. By swapping genetic elements between γRV and lentiviral vectors (LVs), we have demonstrated that transcriptionally active long terminal repeats (LTRs) are major determinants of genotoxicity even when reconstituted in LVs and that self-inactivating (SIN) LTRs enhance the safety of γRVs. By comparing the genotoxicity of vectors with matched active LTRs, we were able to determine that substantially greater LV integration loads are required to approach the same oncogenic risk as γRVs. This difference in facilitating oncogenesis is likely to be explained by the observed preferential targeting of cancer genes by γRVs. This integration-site bias was intrinsic to γRVs, as it was also observed for SIN γRVs that lacked genotoxicity in our model. Our findings strongly support the use of SIN viral vector platforms and show that ISS can substantially modulate genotoxicity.

23 April 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BBBrian D Brown
Brian D Brown
MARY ANNA VENNERIMARY ANNA VENNERI
MARY ANNA VENNERI
AZAnna Zingale
Anna Zingale
LSLucia Sergi Sergi
Lucia Sergi Sergi
LNLuigi Naldini
Luigi Naldini

15 December 2007 in Blood
Verified
Journal Article
Closed access
PDF file
BBBrian D. Brown
Brian D. Brown
ACAlessio Cantore
Alessio Cantore
AAAndrea Annoni
Andrea Annoni
LSLucia Sergi Sergi
Lucia Sergi Sergi
ALAngelo Lombardo
Angelo Lombardo
LNLuigi Naldini
Luigi Naldini
A longstanding goal for the treatment of hemophilia B is the development of a gene transfer strategy that can maintain sustained production of clotting factor IX (F.IX) in the absence of an immune response. To this end, we have sought to use lentiviral vectors (LVs) as a means for systemic gene transfer. Unfortunately, initial evaluation of LVs expressing F.IX from hepatocyte-specific promoters failed to achieve sustained F.IX expression in hemophilia B mice due to the induction of an anti-F.IX cellular immune response. Further analysis suggested that this may be a result of off-target transgene expression in hematopoietic-lineage cells of the spleen. In order to overcome this problem, we modified our vector to contain a target sequence for the hematopoietic-specific microRNA, miR-142-3p. This eliminated off-target expression in hematopoietic cells, and enabled sustained gene transfer in hemophilia B mice for more than 280 days after injection. Treated mice had more than 10% normal F.IX activity, no detectable anti-F.IX antibodies, and were unresponsive to F.IX immunization. Importantly, the mice survived tail-clip challenge, thus demonstrating phenotypic correction of their bleeding diathesis. This work, which is among the first applications to exploit the microRNA regulatory pathway, provides the basis for a promising new therapy for the treatment of hemophilia B.

29 September 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SMStefania Mazzoleni
Stefania Mazzoleni
LPLetterio S. Politi
Letterio S. Politi
MPMauro Pala
Mauro Pala
MCManuela Cominelli
Manuela Cominelli
AFAlberto Franzin
Alberto Franzin
RGRossella Galli
Rossella Galli
Epidermal growth factor receptor (EGFR) is a known diagnostic and, although controversial, prognostic marker of human glioblastoma multiforme (GBM). However, its functional role and biological significance in GBM remain elusive. Here, we show that multiple GBM cell subpopulations could be purified from the specimens of patients with GBM and from cancer stem cell (CSC) lines based on the expression of EGFR and of other putative CSC markers. All these subpopulations are molecularly and functionally distinct, are tumorigenic, and need to express EGFR to promote experimental tumorigenesis. Among them, EGFR-expressing tumor-initiating cells (TIC) display the most malignant functional and molecular phenotype. Accordingly, modulation of EGFR expression by gain-of-function and loss-of-function strategies in GBM CSC lines enhances and reduces their tumorigenic ability, respectively, suggesting that EGFR plays a fundamental role in gliomagenesis. These findings open up the possibility of new therapeutically relevant scenarios, as the presence of functionally heterogeneous EGFRpos and EGFRneg TIC subpopulations within the same tumor might affect clinical response to treatment. Cancer Res; 70(19); 7500–13. ©2010 AACR.